Generic drugmakers Teva and Sandoz make major push to biosimilars | Reuters
A Personalized Approach to Biological Therapy Using Prediction of Clinical Response Based on MRP8/14 Serum Complex Levels in Rheumatoid Arthritis Patients | PLOS ONE
Managing Rheumatic and Immunocompromised Diseases During COVID-19
Frontiers | Introducing Patterns of Variability for Overcoming Compensatory Adaptation of the Immune System to Immunomodulatory Agents: A Novel Method for Improving Clinical Response to Anti-TNF Therapies
Overview of Biosimilars for Immune-Mediated Inflammatory Diseases: Summary of Current Evidence
Topical nanocarriers for management of Rheumatoid Arthritis: A review - ScienceDirect
Chemokine receptor CCR1: new target for asthma therapy: Trends in Pharmacological Sciences
Biologics in severe asthma: the role of real-world evidence from registries | European Respiratory Society
About TRUXIMA® (rituximab-abbs) | Rheumatoid Arthritis | See Safety Info
Frontiers | Past, Present, and Future of Rituximab—The World's First Oncology Monoclonal Antibody Therapy
Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial - The Lancet
About TRUXIMA® (rituximab-abbs) | Rheumatoid Arthritis | See Safety Info
Which Biologic Therapies to Treat Active Rheumatoid Arthritis and When? - European Medical Journal
Nocebos in rheumatology: emerging concepts and their implications for clinical practice | Nature Reviews Rheumatology
Unresolved issues in biologic therapy for rheumatoid arthritis | Nature Reviews Rheumatology
Safety of biologic therapy in rheumatoid arthritis | Nature Reviews Rheumatology
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update | Annals of the Rheumatic Diseases
Infections in patients with rheumatoid arthritis receiving tofacitinib versus tumour necrosis factor inhibitors: results from the open-label, randomised controlled ORAL Surveillance trial | Annals of the Rheumatic Diseases
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update | Annals of the Rheumatic Diseases
Top developments in biosimilars during 2019 - GaBI Journal
Frequency of biologic switching and the outcomes of switching in children and young people with juvenile idiopathic arthritis: a national cohort study - The Lancet Rheumatology
Treatment of Rheumatoid Arthritis with Biological Agents | IntechOpen
